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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) pandemic has continued unabated for nearly 30
years. To better understand the influence of virus on host cells, we performed the differential proteome research of
peripheral blood mononuclear cells (PBMCs) from HIV-positive patients and healthy controls.
Results: 26 protein spots with more than 1.5-fold difference were detected in two dimensional electrophoresis
(2DE) gels. 12 unique up-regulated and one down-regulated proteins were identified in HIV-positive patients
compared with healthy donors. The mRNA expression of 10 genes was analyzed by real time RT-PCR. It shows that
the mRNA expression of talin-1, vinculin and coronin-1C were up-regulated in HIV positive patients and consistent
with protein expression. Western blotting analysis confirmed the induction of fragments of vinculin, talin-1 and
filamin-A in pooled and most part of individual HIV-positive clinical samples. Bioinformatic analysis showed that a
wide host protein network was disrupted in HIV-positive patients.
Conclusions: Together, this work provided useful information to facilitate further investigation of the underlying
mechanism of HIV and host cell protein interactions, and discovered novel potential biomarkers such as fragment
of vinculin, filamin-A and talin-1 for anti-HIV research.
Background
The human immunodeficiency virus type 1 (HIV-1)
pandemic has continued unabated for nearly 30 years.
Globally, there are estimated 33.4 million living indivi-
duals in 2008 according to AIDS epidemic update 2009
by the World Health Organization (WHO) http://www.
unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/
EpiUpdArchive/2009/default.asp. Current therapies
direct against viral proteins. Highly active anti-retroviral
therapy has been problematic because of long-term toxi-
city, inhibitor resistance, and the inability to target per-
sistent reservoirs[1,2]. Thus, there is a need for the
comprehensive elucidation of HIV-1-mediated effects on
host cellular protein networks and unique protein tar-
gets for the design of therapeutic drugs.
Over the past few decades, HIV-mediated effects on
host cells have typically involved the study of one gene
or one protein at a time, to elucidate their functions in
lymphocyte or monocyte biology, signaling pathways or
immune system [3-5]. However, the method for one
gene or one protein is too slow to elucidate HIV
mediated effects on host cells.
The advent of proteomics has expanded the focus on
cellular function from examination of gene structure
and function to the analysis of their encoded proteins.
Analyzing encoded proteins is an important advance
because proteins are ultimately responsible for control-
ling most aspects of cellular function, can be regulated
by post-translation modification (PTM), and can not be
ascertained from simple analysis of gene transcription or
translation. Proteomics has been widely used in the
study of pathogenesis, etiology and pathology of infec-
tious disorders such as HIV/HIV-positive, tuberculosis,
malaria, measles, and hepatitis as reviewed by LIST EO.
et al[6] Through proteome research, researchers found
some new possible biomarkers for HIV-associated cog-
nitive neurological disorders (HAND) diagnosis, such as
Cu/Zn superoxide dismutase (Cu/Zn SOD), new treating
targets such as PDI-A3 which were up-regulated after
zidovudine (AZT) treatment [7]. Furthermore, great
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any medium, provided the original work is properly cited.progress was obtained in virus-host cell interaction. For
example, HIV replication enhances the production of
free fatty acids, low density lipoproteins and many key
proteins involved in lipid metabolism[8]. Viral infection
down-regulates matrix metalloproteinase 9 (MMP 9)
secretion[9]. These observations show the potential
power of proteomics for the analysis of cellular proteins
involved in diseases.
Peripheral blood mononuclear cells (PBMCs) have
been recognized as key players in the innate and adap-
tive immune responses for their ability to recognize
molecular patterns that are typical of microorganisms
and by their molecular and functional adaptation to
invade pathogens [10,11]. Currently, PBMCs are widely
used in research and clinical practice, especially in HIV-
positive patients [12]. According to previous reports
[13-15] carried in PBMC, human immunodeficiency
virus type 1 (HIV-1) infections are associated with func-
tional defects in CD4 T cells, marked by unresponsive-
ness to T-cell signaling, as well as an increased
propensity to mitochondrial membrane potential and
apoptosis. Several researches [16-18] have shown that
HIV-1 induced a lot of changes in host cellular proteins,
including caspase 9 and caspase 3-dependent apoptosis,
intracellular transport, oxidative stress, etc.H o w e v e r ,
our knowledge is limited to understand such a compli-
cated virus-host interaction.
In this study, we analyzed HIV-1-mediated effects on
host cellular networks through PBMCs proteomics.
PBMCs were isolated from EDTA-anticoagulated blood
collected from HIV-positive patients or healthy donors
by ficoll density centrifugation. Proteins of PBMCs were
extracted and separated by two-dimensional gel electro-
phoresis (2DE). The differentially expressed proteins
between HIV-positive and healthy donors were identi-
fied by ESI-Ion trap and MALDI-TOF/TOF mass spec-
trometry. The mRNA expression of 10 genes was
analyzed by real time RT-PCR. The expression of talin-
1, filamin-A, GNB1 and vinculin was further validated
by western blotting analysis. Presented data provided
novel insights into HIV and host interaction. Potential
new biomarkers were found, including fragment of vin-
culin for anti-HIV research.
Methods
Human subjects
43 HIV-positive patients and 42 healthy donors were
enrolled in this study (Table 1), including 9, 22 and 12
from patients and 11, 20 and 11 from healthy donors
for two dimensional electrophoresis (2DE), PCR and
western blotting (WB), respectively. Patients with HIV
infection who did not receive antiviral treatment or
immunotherapy in the past 6 months and were followed
up at Shanghai Public Health Clinical Center were
recruited. All patients met the diagnostic criteria of
HIV-positive with CD4 < 350/μL, and negative for hepa-
titis C virus (HCV) and hepatitis B virus (HBV). Blood
samples of healthy donors were the remaining samples
after medical tests ordered by the physicians at Shanghai
Public Health Clinical Center, and were tested negative
for human HIV, HBV and HCV. The study protocol
was approved by the local Ethics Committee, and all
patients were given a written informed consent.
PBMCs separation and detection
Peripheral whole blood (5 mL) was collected into an
EDTA-anticoagulated tube. PBMCs were isolated via
density gradient centrifugation using Ficoll-Paque™ Plus
(Amersham Pharmacia Biotech) according to the manu-
facturer’s instructions. After ficoll density gradient cen-
trifugation, the upper suspension was removed softly,
and the white PBMCS were absorbed and washed twice
with PBS by low-speed centrifugations (200 g, 10 min).
90 percent of collected PBMC pellets were frozen at
-80°C within 4 h from blood collection for proteomic
research. The rest was diluted to 200 μLP B Sa n du s e d
for platelet count through analyzed by Blood Cell Analy-
sis Instrument (Cell-Dyn3200, Abbott, Washington,
98057 USA) using standard clinical detection method
which meets US Clinical Laboratory Improvement
Amendments of 1988 guidelines for AHA performance
standard [19].
2DE and image analysis
2DE was performed with the IPGphor system (GE (for-
merly Amersham Bioscience), USA) and PROTEAN II
system (Bio-Rad, Hercules, California), as previously
described [20]. Briefly, IPG dry strips (pH 3-10 NL (180
× 30 × 0.5 mm)) was used. Isoelectricfocusing (IEF) was
conduced automatically to a total of 52.1 KVh. After
equilibration, proteins were separated in 11.5% separa-
tion gels with 25 mA/gel constant current. The separa-
tion gels were made by us according to the standard
protocol described by Gorg et al[21]. Three couples of
2-D gels with protein load of 250 μg were stained by sil-
ver nitrate for image analysis. Another couple of 2-D
gels with protein load of 1,000 μg were stained with
Coomassie brilliant blue (CBB) for protein identification.
For image analysis, Imagemaster 2D software (GE
Company, USA) was used according to the manufac-
turer. Briefly, the individual spot volumes were normal-
ized by dividing their optical density (OD) values by the
total OD values of all the spots on the gel to remove
the artificial factors. The three parallel gels from HIV-
positive or healthy donors were divided into a group
respectively, and the matched spots in the three parallel
gels were averaged respectively. The threshold defined
as the significant change in relative spot volume was at
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positive with that of healthy donors.
Trypsin Digestion and Protein identification
T h ep r o t e i ns p o t sw e r em a n u a l l ye x c i s e d ,a n di n - g e l
digested as described [20,22]. The digested peptides
were analyzed by esquire high capacity ion trap (HCT)
mass spectrometer (Bruker, Germany) and MALDI-
TOF/TOF (Bruker, Germany). For HCT analysis, the
tryptic peptide mixtures were injected onto a C18 μ-pre-
column (300 μm id × 5 mm, 5 μm, PepMap™) (LC Pack-
ings, Amsterdam, the Netherlands) with a flow rate of
20 μL/min in Ultimate 3000 (Dionex Corporation,
USA). After desalted by precolumn, the peptides were
eluted to a C-18 reversed-phase nanocolumn (75 μmi d
×1 5c ml e n g t h ,3μm, PepMap™) (LC Packings) using a
3-50% continuous acetonitrile gradient at 300 nL/min.
The eluted peptides from the reversed-phase nanocol-
umn were on line injected to a PicoTip emitter nanos-
pray needle (New Objective, Woburn, MA, USA) for
real-time ionization and peptide fragmentation on HCT
mass spectrometer.
For MALDI-TOF/TOF analysis, the tryptic peptide
mixtures were loaded onto a 384 AnchorChip target
(Bruker Daltonik, Bremen, Germany) and analyzed by
mass spectrometry according to our published papers
[20,22,23].
The MS/MS data was input to MASCOT 2.0 program
(MatrixScience, Boston, MA, USA) to search against
SwissProt 54.8 identification. Search parameters were set
as follows: enzyme, trypsin; allowance for up to one
missed cleavage peptide; mass tolerance, 1.2 Da for
HCT and 50 ppm for MALDI-TOF/TOF, and MS/MS
mass tolerance, 0.6 Da; fixed modification parameter,
carbamoylmethylation (C); variable modification para-
meters, oxidation (at Met); auto hits allowed (only
significant hits were report); results format as peptide
summary report. Proteins were identified on the basis of
peptides whose ions scores exceeded the threshold (p <
0.05), which indicates identification at the 95% confi-
dence level for these matched peptides. For HCT data,
proteins identified by more than 4 peptides were
accepted and each peptide was manually inspected. Of
w h i c h ,t h e r em u s tb eap e p t i d ew i t hf o u ro rm o r ec o n -
tinue y-or b-series ions (e.g., y4, y5, y6, y7). For
MALDI-TOF/TOF analysis, only proteins with scores
over 62 were accepted.
Data analysis and bioinformatics
The function of the identified proteins was elucidated by
SWISS-PROT database http://www.expasy.org and the
interaction between the differentially expressed proteins
and HIV proteins were checked by HIV interaction data-
base http://www.ncbi.nlm.nih.gov/RefSeq/HIVInterac-
tions. A protein-protein interaction network was drawn
by STRING 8.0 http://string.embl.de/ using proteins
identified in this work and data from SWISS-PROT func-
tion annotation as input. Cytoscape software was used to
integrate human proteins with HIV proteins to draw a
protein-protein interaction of HIV and host cell proteins.
RNA extraction and quantitative real-time RT-PCR
Total RNA from PBMCs was extracted using Trizol
reagent (Invitrogen Life Technologies) following the man-
ufacturer’s instructions and the described previously[5].
Briefly, real-time PCR was performed in the iCycler iQ
Multicolor Real-Time PCR Detection System (Bio-Rad
Laboratories) using the SYBR Green (ToYoBo). 2 μl
cDNA templates was used for each PCR with 0.7 μl1 0
nM sense and antisense primers (Table 2) in a total
volume of 25 μl. The thermal cycling conditions com-
prised 3 min at 95°C, followed by 40 cycles at 95°C for 5 s,
Table 1 Characteristics of patients with HIV and healthy donors
Parameter Patients Healthy donors
2DE PCR WB 2DE PCR WB
Number 9 22 12 11 20 11
Age 40.5 ± 10.3 42.1 ± 12.0 44.0 ± 9.4 38.5 ± 11.6 41.3 ± 12.3 41.0 ± 10.1
Female 2 3 4 2 4 4
HIV Yes No
HBV No No
HCV No No
CD4 <350 /
Selection criteria
1. 18 to 60 years old;
2. Consistent with the diagnostic criteria of HIV infection according to the guidelines of prevention and treatment for HIV-positive in China;
a) The clinical history of HIV-positive;
b) CD4<350/μL;
3. Have not received antiviral treatment or immunotherapy;
4. Negative for other viral infections, including HCV and HBV according to antibody test.
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performed in duplicate. The threshold cycle of each PCR
was converted to a DNA equivalent by reading standard
curves generated by amplifying dilutions of a linearized
plasmid containing the 188 bp GAPDH cDNA. The rela-
tive quantity of the target mRNA was normalized to the
level of the internal control GAPDH mRNA level.
Western blotting and densitometry analysis
Fifty micrograms of total protein extracts from pooled
and individual samples (12 HIV-positive patients and 8
healthy donors for GNB1, talin-1, vinculin and filamin A)
were separated by electrophoresis in SDS-10% polyacryla-
mide gel and transferred to PVDF membrane (Millipore).
After blocking in 10% defatted milk for 2 h, blots were
incubated overnight at 4°C with specific primary antibo-
dies (GNB1, 1:2000; talin-1, 1:1000; filamin A, 1:5000,
viculin, 1:2000). After three washes with TBS-Tween-20,
blots were incubated for 1 h at 20°C with secondary anti-
body. After further washes, the immune complexes were
revealed by enhanced chemiluminescence and detected
by X-rays. Each experiment was repeated for three times.
Statistical Analysis
For all studies, experiments were repeated at least twice.
For quantitative data, means and P value were com-
puted. For platelet count and real-time RT-PCR, Mann-
Whitney Test was used. For protein spot density in
2DE, a Two-sample t Test software analysis packed in
Imagemaster software was used.
Results
PBMC analysis
After Ficoll centrifugation, the white blood cell ring frac-
tion (about 2*10
6 PBMCs/5 mL whole blood) was col-
lected and used for PBMC quality analysis or proteomic
research. To check the contamination of platelets, the
blood cell analysis was carried. As shown in Additional
file 1, table S1, 25.2 ± 27.8 (average ± std, n = 13) and
24.1 ± 24.4e*10
9/L (average ± std, n = 11) platelets were
detected in the PBMCs from 13 healthy controls and 11
HIV-positive patients respectively. The platelets were
reduced for 4 to 12-fold compared with normal reference
(100 to 300)*10
9/L. No statistic difference was found
between HIV-positive patients and healthy controls
through Mann-Whitney Test statistic analysis (P = 0.34).
2-DE and the analysis of gel images
Proteins can be well separated through pH3-10 NL gel
stripe in the first dimension and 11.5% separation gel in
the second dimension. 1275 ± 242 and 1091 ± 172 protein
spots were detected in silver-stained 2DE gels of the HIV-
positive and the controls through ImageMaster software
analysis and confirmed by manually checking. A typical
Table 2 Quantitative analysis results of mRNA expression of 10 differentially expressed proteins in PBMCs from HIV-
positive patients and healthy donors.
gene name strand primer Aaymp. Sig.(2-tailed) Number
(HIV/Normal)
Mean peak
(HIV/Normal)
Expression of proteins
in HIV
KPYM sense ctatcctctggaggctgtgc 0.029 10/10 0.6 ↑11.9
antisense ccagacttggtgaggacgat
TLN1 sense tctcccaaaatgccaagaac 0.022 20/22 1.5 ↑4.1
antisense ctccactagcccttgctgtc
CAP1 sense gtgtcaacagccagcagaaa 0.004 10/10 0.8 Only
antisense gcggcatcattcatttcttt
ENOA sense gagctccgggacaatgataa 0.631 10/10 1.1 Only
antisense tgttccatccatctcgatca
EHD3 sense ctaaccctgtgctggagagc 0.009 10/10 0.8 Only
antisense gtcagctttgttcagcacca
COR1C sense gcagaagagtggttcgaagg 0.047 20/22 1.4 ↑2.0
antisense tgatcaggtcgcacttcttg
ST1A3 sense catgaaggagaaccccaaaa 0.739 10/10 1.1 ↑1.8
antisense tgaaggtggtcttccagtcc
FLNA sense aagtgaccgccaataacgac 0.393 10/10 0.8 ↑1.7
antisense ggcgtcaccctgtgacttat
VINC sense gccaagcagtgcacagataa 0.007 20/22 1.6 ↑14.1
antisense tctttctaacccagcgcagt
GNB1 sense cttgtgatgcttcagccaaa 0.078 20/22 1.4 ↓1.5
antisense tcagcacgaaggtcaaacag
Isolated PBMCs from HIV-positive and healthy donors were treated with Trizol regent and RNA was extracted according to the manufacturer’s instructions. The
primers were obtained through primer 3.0 software analysis. The data were statistic analyzed through Mann-Whitney test.
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HIV-positive patients and healthy controls was shown in
Figure 1. 26 protein spots with 1.5 or more fold difference
were detected. The partially magnified images of five pro-
tein spots including talin-1(TLN1) (spot 2), filamin-A
(FLNA) (spot 9), etc. were shown in Figure 2A.
Protein identification
As shown in Table 3 and Figure 1, 20 differentially
expressed spots were successfully identified which corre-
sponding to 13 non-redundant proteins identified by
HCT with more than four peptides, four of which were
simultaneously identified by MALDI-TOF/TOF (Addi-
tional file 2, Table S2). These four proteins identified by
both HCT and MALDI-TOF/TOF were talin-1, filamin-
A, vinculin and EH domain-containing protein 3 with
increased expression in HIV-positive patients compared
with healthy controls. According to annotations from
UniProt knowledgebase (Swiss-Prot/TrEMBL) and Gene
Ontology Database, the identified proteins were involved
in various cellular functions including binding (7 pro-
teins), enzyme (4 proteins), signal transduction (2 pro-
teins) and immune response (one protein). In particular,
most of the differential proteins (58%) were membrane
proteins such as talin-1, filamin-A, etc.F u r t h e r m o r e ,
many different spots were identified to be the products
of the same gene such as actin(ACTB), adenylyl cyclase-
associated protein 1 (CAP1) and alpha-enolase (ENOA).
Protein-protein interaction
As we know, HIV infection is depending on the interac-
tion between HIV proteins and host cell proteins. In this
work, bioinformatics analysis was performed to elucidate
the network between the identified differential proteins
and HIV function proteins. As shown in Figure 3, a wide
protein-protein interaction network was affected in HIV/
AIDS patients. For example, the host protein interaction
net such as VCL - TLN1 - actin, cytoplasmic 2(ACTG1)
- FLNA was found to interact with nef and pol (HIV
function proteins), and be substantially up-regulated in
HIV/AIDS patients. The similar result was observed in
ENOA-(L-lactate dehydrogenase B chain) LDHB - pyru-
vate kinase isozymes M1/M2 (PK3) network which inter-
acting with rev, gp41 and gp120 (HIV function proteins).
The related network-protein information is listed in
Additional file 3, Table S3.
Transcriptional profiles of differentially expressed
proteins
In order to make sure whether the protein expression
change happens at the transcriptional or translational
level, the transcriptional alterations of 10 selected genes in
PBMCs from HIV-infected patients (10 or 20) and healthy
donors (10 or 22) were measured by quantitative real-time
RT-PCR using the mRNA transcript of GAPDH as a con-
trol housekeeping gene. As shown in Table 2 and Figure 4,
VINC, TLN1, CAP1, pyruvate kinase isozymes M1/M2
Figure 1 CBB-stained 2-DE gels of HIV-positive (A) and healthy donors (B). Each sample (1000 μg) was subjected to 2DE and CBB staining.
Molecular weight of markers is shown on the left. The identified differential proteins (p < 0.05) were marked in gels. Proteins up-regulated in
HIV/AIDS were marked in Figure 1A, that down-regulated in Figure 1B.
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coronin-1C (COR1C) were found to be statistically differ-
ent between HIV-positive patient and healthy donors. The
expression of VINC, TLN1 and COR1C was up-regulated
by 1.5, 1.6 and 1.4 fold, respectively, which was consistent
with the results from 2DE-MS. In contrast, KPYM has the
contrast result with 2DE-MS, down-regulated by 1.7-fold.
CAP1 and EHD3 were changed a little with about 0.8 to
1.2- fold differences respectively. FLNA, GNB1, alpha-eno-
lase (ENOA) and sulfotransferase 1A3/1A4 (ST1A3), were
found to be no difference between HIV-positive and
healthy donors.
Figure 2 Western blotting verification of part of the differential proteins. A. Partially magnified images of five protein spots in 2D gels. B.
Western blotting confirmation of talin-1, filamin-A, vinculin and GNB1 in pooled samples. C. Western blotting of GNB1, talin-1, vinculin and
filamin-A in 23 individuals (12 from patients and 11 from healthy controls). GAPDH was used as the internal control.
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To further confirm the alterations of protein expression
between HIV-positive and healthy donors, four pro-
teins–talin-1, filamin A, vinculin and GNB1 were
selected for western blotting analysis through pooled
and 23 individual samples including 12 from patients
and 11 from healthy controls. For vinculin, a fragment
with molecular weight of about 80 KDa was over
expressed in pooled and almost all the HIV-positive
samples (Figure 2B, 2C), which was consistent with that
of 2DE. For talin-1, a fragment with 38 KDa was found
in pooled samples from HIV-positive patients;
Table 3 List of the differentially expressed protein spots in 2DE of HIV-positive and healthy donors identified by ESI-
MS or both ESI-MS and MALDI-TOF/TOF.
spot
a Accession NO.
b Protein description MW
c pI Score
d Cov.
e Abundance
HIV/NOR
Function
f Location
g
1 KPYM_HUMAN Pyruvate kinase isozymes M1/M2 -
Homo sapiens (Human)
58470 7.96 173 15% ↑ enzyme Cytosol
2 TLN1_HUMAN Talin-1 - Homo sapiens (Human) 271766 5.77 44 2% ↑ cell-cell
junction
Cell membrane;
Cell projection;
Cytoplasm;
Cytoskeleton;
Membrane.
3 LDHB_HUMAN L-lactate dehydrogenase B chain -
Homo sapiens (Human)
36900 5.71 316 30% ↑ enzyme Cytoplasm.
4, 14, 15 CAP1_HUMAN Adenylyl cyclase-associated protein
1 - Homo sapiens (Human)
52222 8.27 129 16% ↑ actin
binding
Cell membrane;
PM
5, 13, 16, 19 ENOA_HUMAN Alpha-enolase - Homo sapiens
(Human)
47481 7.01 217 34% ↑ Enzyme Cell membrane;
Cytoplasm;
Membrane;
Nucleus.
6 EHD3_HUMAN EH domain-containing protein 3 -
Homo sapiens (Human)
61971 6.06 285 36% ↑ Binding/
transport
Cell membrane;
Endosome.
Membrane
7 COR1C_HUMAN Coronin-1C - Homo sapiens
(Human)
53899 6.65 253 18% ↑ Actin-
binding/
transport
actin cytoskeleton
8 ST1A3_HUMAN Sulfotransferase 1A3/1A4 - Homo
sapiens (Human)
34288 5.68 85 23% ↑ Actin-
binding/
transport
Cytoplasm
9 FLNA_HUMAN Filamin-A - Homo sapiens (Human) 283301 5.7 172 9% ↑ Actin-
binding
Cytoplasm;
Cytoskeleton;
plasma
membrane.
10 VINC_HUMAN Vinculin - Homo sapiens (Human) 124292 5.5 755 26% ↑ actin
binding
Cytoplasm;
cytoskeleton;
Cell junction;
adherens junction;
Cell membrane;
Peripheral
membrane
protein;
11 IGKC_HUMAN Ig kappa chain C region - Homo
sapiens (Human)
11773 5.58 101 80% ↑ immuno extracellular
region
12 GNB1_HUMAN Guanine nucleotide-binding protein
G(I)/G(S)/G(T) subunit beta-1 -
Homo sapiens (Human)
38151 5.6 69 31% ↓ transducer
17, 18, 20 ACTB_HUMAN Actin, cytoplasmic 1 42052 5.29 119 29% ↑ ATP
binding
Cytoplasm;
cytoskeleton.
aSpot no. is the unique number which refers to the labels in Figure 1. Protein spots identified by ESI and MALDI were highlighted by bold and italic.
bAccession no. is the MASCOT results of ESI-Ion trap searched from the SWISS-PROT database.
c Molecular weight predicted from database.
d Mascot score was selected identified by HCT.
e Sequence coverage (%) means the number of amino acids spanned by the assigned peptides divided by the sequence length.
fProtein function from SWISS-PROT database
g Protein location from SWISS-PROT database
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differentially expressed proteins identified in our work. Proteins labeled in red character were HIV proteins. The rest proteins were host proteins
from the database.
Figure 4 The mRNA expression of six genes selected from 13 differentially expressed proteins (p < 0.05). TLN1-H and TLN1-N represent
TLN1 from HIV-positive patients and healthy controls respectively.
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the other two fragments seen from figure 2B. Through
further WB verification (focusing on this fragment) in
the 23 individual samples, we found that this fragment
could be detected in 10 HIV-positive individuals. How-
ever, no positive signal was detected in any healthy con-
trols (figure 2C). For filamin-A, three bands were
detected in the samples from healthy donors, while one
more band with molecular weight about 70 kDa was
found in the pooled and 10 individual samples (Figure
2B, 2C). For GNB1, about 1.8-fold decrease was detected
in pooled HIV-1 positive samples. However, GNB1 was
found to be down-regulated only in 5 samples of HIV-
positive individuals (1, 2, 4, 5 and 11) (Figure 2C).
Through statistic analysis, no significant difference (p >
0.05, data not shown) was detected in HIV-positive
patients seeing from our study.
Discussion
The composition of PBMCs may not be constant due to
the contamination from red cells and platelets especially
platelets. So, it is important to separate PBMCs accord-
ing to standard protocol. In this work, we separated the
PBMCs according to Ficoll-Paque Plus protocol (recom-
mended by Amersham Pharmacia Biotech), and stored
them at -80°C within 4 h for proteomic research to
decrease artificial difference due to sample treatment
and storage. Especially, in order to decrease platelet’s
contamination, four tips were used, including 1) ficoll
density gradient centrifugation; 2) softly removing the
upper suspension after gradient centrifugation; 3) only
absorbing the white PBMCS fraction; 4) PBS wash for
twice using low-speed centrifugations (200 g, 10 min).
Due to the above matters, the platelets were not only
decreased for 4 to 12 fold, but also no significant differ-
ence was detected in two kinds of samples through
Mann-Whitey Test statistic analysis of PBMCS from 12
HIV-positive patients and 9 healthy controls. This indi-
cates that the methods reported in this study are reliable
and there is no artificial difference during PBMC
separation.
For clinical proteomics, it is one of the main considers
to decrease the individual variation. In this work, the
sample sizes were at least 9. According to the liver pro-
teomic results reported by He Fuchu et al., the indivi-
dual variation was not significant when the sample size
exceeded 7 [20]. Considering the higher individual varia-
tion in HIV-infected patients, and referring the HIV-
related proteomic research [24-26], the sample size used
in work was at least 9. So according to our knowledge,
the sample size in this work is basically suitable for pro-
teomic research.
Increasing evidence emphasizes comparative proteomics
to screen the differentially expressed proteins associated
with HIV/AIDS [6,27]. In our study, we obtained a 2DE
profile of the altered protein expression of HIV-positive
compared with healthy donors. 13 non-redundant differ-
entially expressed proteins were identified by MS/MS.
According to their function annotated in SWISS-PROT
http://www.expasy.org, these differentially expressed pro-
teins can be classified into four categories (Table 3).
Seven of the differentially expressed proteins have
binding function, which were talin-1, filamin-A, vinculin,
coronin-1C, EH domain-containing protein 3, adenylyl
cyclase-associated protein 1 and actin. Many studies
have shown that the level of talin-1 correlates with HIV
infection[28,29]. HIV-1-infected effector T cells binding
to primary CD4/CXCR4-targeted T cells results in rapid
recruitment to the interface of CD4, CXCR4 and talin
[28]. Talin head domain, a fragment of COOH terminus,
was reported to be an immunodominant epitope of the
antiplatelet antibody response in patients with HIV-1-
associated thrombocytopenia[29]. In this study, a new
fragment of about 38 kDa was detected. This new frag-
ment might be degraded by HIV [29], or produced dur-
ing the host cell apoptosis processing for talin involved
in cell membrane receptor mediated apoptosis pathway
[30] and caspase-mediated cleavage[31]. Vinculin has
high affinity to talin-1 [32], and is involved in the
attachment of the actin-based microfilaments to the
plasma membrane, plays important roles in cell mor-
phology and locomotion [33,34]. Vinculin can be
induced to polarizate by HIV-1 Nef [35], were detected
to be a caspase-3 target and over-expressed in apoptotic
cells [36]. So the fragment detected in this study might
be the degradation product of vinculin and can be used
as a marker for cell apoptosis in HIV-positive patients.
In this work, we also identify another cytoskeleton pro-
tein–filamin A, which can interact with pol (a HIV pro-
tein), and was reported to be an adaptor protein that
links HIV-1 receptors to the actin cytoskeleton remodel-
ling machinery[37]. Filamin A can be cleaved from 280
kDa to 170, 150, and 120 kDa major N-terminal frag-
ments, and 135, 120, and 110 kDa major C-terminal
f r a g m e n t sw h e na p o p t o s i sw a si n d u c e d [ 3 8 ] .T h e2 8 0
kDa representing filamin was decreased in HIV-positive
patients [39]. In our research, a fragment with molecular
weight of about 70 kDa derived from the COOH termi-
n u so ff i l a m i nAw a si n c r e a s e d .S ot h i sf r a g m e n tm i g h t
be the product of filamin A cleaved by HIV or proteo-
lyzed during apoptosis for filamin are involved in cas-
pase pathway and can be cleaved in HIV-positive
patients. These results are consistent with the present
knowledge that HIV induces host cell apoptosis through
degrading the proteins related to actin cytoskeletal
network.
Four of the proteins were enzymes including L-lactate
dehydrogenase B chain, pyruvate kinase isozymes
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transferase 1A3/1A4. Lactate dehydrogenase B can
interact with gp120 and gp41. It was found to be up-
regulated by HIV-1 gp120/41 [40]. Pyruvate kinase iso-
zymes M1/M2, a glycolytic enzyme that catalyzes the
transfer of a phosphoryl group from phosphoenolpyru-
vate (PEP) to ADP [41], was found to be down-regulated
in HIV-1-infected mouse astrocytes[42] and microglia
[16]. However, opposite result was found in PBMCs of
HIV-positive patients. This result may be due to 1) the
difference between in vitro and in vivo protein expres-
sion, 2) the difference between PBMCs and astrocytes or
microglia. Adenylyl cyclase-associated protein 1 is an
metabolism enzyme involved in carbohydrate degrada-
tion and glycolysis[43]. Sulfotransferase 1A3/1A4 cata-
lyzes the sulfate conjugation of phenolic monoamines, is
an important lipid metabolism enzyme[44]. These up-
regulated enzymes indicated that a stronger enzyme
reaction was induced, and metabolic abnormalities were
developed in HIV-infected patients[8,45].
In this work, we also identified three signal transduc-
tion proteins. They were GNB1, EH domain-containing
protein 3 and coronin-1C. Of which, GNB1 was selected
for further verification for it involved as a modulator or
transducer in various transmembrane signaling systems
[46]. According to the description by Nancy Vazquez
[47], the gene expression of GNB1 was found to be up-
regulated by 5.0-fold in macrophages infected by HIV-1
compared with uninfected cells. Similarly, Sharon M.
Wahl [48] reported that HIV not only induced the up-
regulation of GNB1, but the up-regulation of GNB1
could facilitate HIV-1 replication in macrophages. How-
ever, we detected this protein was down-regulated in
HIV-positive patients analyzed from pooled and part of
individual samples. Maybe it is due to the following rea-
sons: 1) Vazquez [47] and Wahl [48] analyzed GNB1
from gene level. However, there are only 50% consistent
between mRNA level and protein level. 2) Vazquez [47]
and Wahl [48] analyzed GNB1 in vitro (HIV-infected
macrophages). However, we studied it in vivo.M a y b ei t
is due to the difference between in vitro and in vivo.3 )
Vazquez [47] and Wahl [48] reported the up-regulation
of GNB1 in macrophages infected by HIV, while we
detected the down-regulated in PBMCs including other
mononuclear cells as well as macrophages. Further, we
only detected the down-regulated expression of GNB1
in part of samples, so there must be some other factors
affecting the expression of GNB1. Further researches are
needed, such as studying the expression of this protein
in different cell groups. We also found one protein– Ig
kappa chain C region related to immune response[49].
According to bio-informatics, these proteins interact
with each other as shown in Figure 3. HIV infection
affects a wide protein network, some of which were
observed before and many were discovered for the first
time in this work as discussed above.
It is interesting that most of the identified differential
proteins were membrane or membrane-related proteins
with binding function although we did not enrich mem-
brane. The up-regulated membrane protein fragment
further verified the idea that HIV destructed host cells
through degrading the cytokeratin proteins such as talin,
filamin A and vinculin[29,50].
Conclusions
In conclusion, this study adopted a gel-based proteomic
approach to probe changed proteins in PBMCs of HIV-
positive patients. It is noteworthy that the comparative
proteomic approach allowed for the initial identification
of 13 altered cellular proteins in HIV-positive patients
compared with healthy donors and showed most of the
altered cellular proteins are involved in enzyme activa-
tion, cell-connection and signaling transduction. A wide
protein-protein interaction network was affected in
HIV-positive patients. Our study can offer some help in
revealing the interactions between HIV and host cell.
Additional file 1: Table S1 The blood routine analysis results of HIV
positive and healthy samples. No statistical difference of PLA
contamination was found between HIV-positive and healthy blood
samples
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S1.DOC]
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Additional file 3: Table S3 Human proteins and HIV-1 proteins
involved in the protein-protein interaction network. A list of proteins
involved in the protein-protein interaction work
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-5956-8-12-
S3.DOC]
Abbreviations
HIV: human immunodeficiency virus; PBMCs: peripheral blood mononuclear
cells; AIDS: acquired immune deficiency syndrome; HAART: high activity
antiretroviral therapy; GAPDH: glyceraldehyde-3-phosphate dehydrogenase;
HCT: high capacity trap.
Acknowledgements
This work was supported by “Research Foundation for Talented Scholars by
Shanghai Public Clinical Center (RCJJP2)”, “Basic research supported by the
Ministry of Health (WA-2007-04)”, and “National Key Technology R&D
Program of China (Grant No. 2008ZX10001-008)”. We thank Prof. Jianqing Xu
(Fudan University, China) for reviewing this manuscript.
Author details
1Shanghai Public Health Clinical Center affiliated to Fudan University,
Shanghai, 201508, PR China.
2Neurosurgery, Fuzhou General Hospital, Fuzhou
Zhang et al. Proteome Science 2010, 8:12
http://www.proteomesci.com/content/8/1/12
Page 10 of 12350025, PR China.
3Institutes of Biomedical Sciences, Fudan University,
Shanghai, 200032, PR China.
Authors’ contributions
LZ designed the study, participated in statistical analysis of experiment data,
interpret the experiment data and draft the manuscript. XJ carried out
protein identification. XZ, JS and TQ carried out clinical blood sample
collection. XP and CQ carried out PBMCs isolation and 2DE. FM carried out
real time RT-PCR and data analysis. LY and YY participated in western blot.
HL revised the manuscript critically. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 24 November 2009 Accepted: 12 March 2010
Published: 12 March 2010
References
1. O’Brien ME, Clark RA, Besch CL, Myers L, Kissinger P: Patterns and
correlates of discontinuation of the initial HAART regimen in an urban
outpatient cohort. J Acquir Immune Defic Syndr 2003, 34:407-414.
2. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M,
Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M, Telenti A: Prevalence
of adverse events associated with potent antiretroviral treatment: Swiss
HIV Cohort Study. Lancet 2001, 358:1322-1327.
3. Wollscheid B, Watts JD, Aebersold R: Proteomics/genomics and signaling
in lymphocytes. Curr Opin Immunol 2004, 16:337-344.
4. Spetz AL, Patterson BK, Lore K, Andersson J, Holmgren L: Functional gene
transfer of HIV DNA by an HIV receptor-independent mechanism. J
Immunol 1999, 163:736-742.
5. Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, Zhang Q, Wang J, Zhang Z,
Shen F, Yuan Z: Expression profiles and function of Toll-like receptors 2
and 4 in peripheral blood mononuclear cells of chronic hepatitis B
patients. Clin Immunol 2008, 128:400-408.
6. List EO, Berryman DE, Bower B, Sackmann-Sala L, Gosney E, Ding J, Okada S,
Kopchick JJ: The use of proteomics to study infectious diseases. Infect
Disord Drug Targets 2008, 8:31-45.
7. D’Andrea G, Brisdelli F, Bozzi A: AZT: an old drug with new perspectives.
Curr Clin Pharmacol 2008, 3:20-37.
8. Rasheed S, Yan JS, Lau A, Chan AS: HIV replication enhances production
of free fatty acids, low density lipoproteins and many key proteins
involved in lipid metabolism: a proteomics study. PLoS ONE 2008, 3:
e3003.
9. Ciborowski P, Enose Y, Mack A, Fladseth M, Gendelman HE: Diminished
matrix metalloproteinase 9 secretion in human immunodeficiency virus-
infected mononuclear phagocytes: modulation of innate immunity and
implications for neurological disease. J Neuroimmunol 2004, 157:11-16.
10. Barrett L, Gallant M, Howley C, Bowmer MI, Hirsch G, Peltekian K, Grant M:
Enhanced IL-10 production in response to hepatitis C virus proteins by
peripheral blood mononuclear cells from human immunodeficiency
virus-monoinfected individuals. BMC Immunol 2008, 9:28.
11. Calarota SA, Foli A, Maserati R, Baldanti F, Paolucci S, Young MA,
Tsoukas CM, Lisziewicz J, Lori F: HIV-1-specific T cell precursors with high
proliferative capacity correlate with low viremia and high CD4 counts in
untreated individuals. J Immunol 2008, 180:5907-5915.
12. Minga AK, Anglaret X, d’ Aquin Toni T, Chaix ML, Dohoun L, Abo Y,
Coulibaly A, Duvignac J, Gabillard D, Rouet F, Rouzioux C: HIV-1 DNA in
peripheral blood mononuclear cells is strongly associated with HIV-1
disease progression in recently infected West African adults. J Acquir
Immune Defic Syndr 2008, 48:350-354.
13. Sternfeld T, Tischleder A, Schuster M, Bogner JR: Mitochondrial membrane
potential and apoptosis of blood mononuclear cells in untreated HIV-1
infected patients. HIV Med 2009, 10:512-519.
14. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, Goujard C,
Debord T, Montagnier L: Programmed cell death in peripheral
lymphocytes from HIV-infected persons: increased susceptibility to
apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation
and with disease progression. J Immunol 1996, 156:3509-3520.
15. Franceschi C, Franceschini MG, Boschini A, Trenti T, Nuzzo C, Castellani G,
Smacchia C, De Rienzo B, Roncaglia R, Portolani M, Pietrosemoli P,
Meacci M, Pecorari M, Sabbatini A, Malorni W, Cossarizza A: Phenotypic
characteristics and tendency to apoptosis of peripheral blood
mononuclear cells from HIV+ long term non progressors. Cell Death Differ
1997, 4:815-823.
16. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, Mosley RL, Volsky DJ,
Ciborowski P, Gendelman HE: Proteomic modeling for HIV-1 infected
microglia-astrocyte crosstalk. PLoS ONE 2008, 3:e2507.
17. He F, Zeng Y, Wu X, Ji Y, He X, Andrus T, Zhu T, Wang T: Endogenous HIV-
1 Vpr-mediated apoptosis and proteome alteration of human T-cell
leukemia virus-1 transformed C8166 cells. Apoptosis 2009, 14:1212-1226.
18. Ringrose JH, Jeeninga RE, Berkhout B, Speijer D: Proteomic studies reveal
coordinated changes in T-cell expression patterns upon infection with
human immunodeficiency virus type 1. J Virol 2008, 82:4320-4330.
19. Xiaobo H, Yong L, Daming J, Lei X, Ying S, Jinfeng Z: External quality
assessment of automated hematology analyzer performance using fresh
human blood samples in Shanghai. Lab Hematol 2003, 9:175-178.
20. Zhang L, Liu X, Zhang J, Cao R, Lin Y, Xie J, Chen P, Sun Y, Li D, Liang S:
Proteome analysis of combined effects of androgen and estrogen on
the mouse mammary gland. Proteomics 2006, 6:487-497.
21. Gorg A, Postel W, Domscheit A, Gunther S: Two-dimensional
electrophoresis with immobilized pH gradients of leaf proteins from
barley (Hordeum vulgare): method, reproducibility and genetic aspects.
Electrophoresis 1988, 9:681-692.
22. Zhang L, Xie J, Wang X, Liu X, Tang X, Cao R, Hu W, Nie S, Fan C, Liang S:
Proteomic analysis of mouse liver plasma membrane: use of differential
extraction to enrich hydrophobic membrane proteins. Proteomics 2005,
5:4510-4524.
23. Zhang L, Wang X, Peng X, Wei Y, Cao R, Liu Z, Xiong J, Ying X, Chen P,
Liang S: Immunoaffinity purification of plasma membrane with
secondary antibody superparamagnetic beads for proteomic analysis. J
Proteome Res 2007, 6:34-43.
24. Wiederin J, Rozek W, Duan F, Ciborowski P: Biomarkers of HIV-1 associated
dementia: proteomic investigation of sera. Proteome Sci 2009, 7:8.
25. Pendyala G, Trauger SA, Kalisiak E, Ellis RJ, Siuzdak G, Fox HS: Cerebrospinal
fluid proteomics reveals potential pathogenic changes in the brains of
SIV-infected monkeys. J Proteome Res 2009, 8:2253-2260.
26. Laspiur JP, Anderson ER, Ciborowski P, Wojna V, Rozek W, Duan F, Mayo R,
Rodriguez E, Plaud-Valentin M, Rodriguez-Orengo J, Gendelman HE,
Melendez LM: CSF proteomic fingerprints for HIV-associated cognitive
impairment. J Neuroimmunol 2007, 192:157-170.
27. Luciano-Montalvo C, Ciborowski P, Duan F, Gendelman HE, Melendez LM:
Proteomic Analyses Associate Cystatin B with Restricted HIV-1
Replication in Placental Macrophages. Placenta 2008, 29:1016-1023.
28. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ: HIV-1 cell to cell transfer
across an Env-induced, actin-dependent synapse. J Exp Med 2004,
199:283-293.
29. Koefoed K, Ditzel HJ: Identification of talin head domain as an
immunodominant epitope of the antiplatelet antibody response in
patients with HIV-1-associated thrombocytopenia. Blood 2004,
104:4054-4062.
30. Foger N, Rangell L, Danilenko DM, Chan AC: Requirement for coronin 1 in
T lymphocyte trafficking and cellular homeostasis. Science 2006,
313:839-842.
31. Lesay A, Hickman JA, Gibson RM: Disruption of focal adhesions mediates
detachment during neuronal apoptosis. Neuroreport 2001, 12:2111-2115.
32. Izard T, Vonrhein C: Structural basis for amplifying vinculin activation by
talin. J Biol Chem 2004, 279:27667-27678.
33. Izard T, Evans G, Borgon RA, Rush CL, Bricogne G, Bois PR: Vinculin
activation by talin through helical bundle conversion. Nature 2004,
427:171-175.
34. Nhieu GT, Izard T: Vinculin binding in its closed conformation by a helix
addition mechanism. Embo J 2007, 26:4588-4596.
35. Quaranta MG, Mattioli B, Spadaro F, Straface E, Giordani L, Ramoni C,
Malorni W, Viora M: HIV-1 Nef triggers Vav-mediated signaling pathway
leading to functional and morphological differentiation of dendritic
cells. Faseb J 2003, 17:2025-2036.
36. Propato A, Cutrona G, Francavilla V, Ulivi M, Schiaffella E, Landt O, Dunbar R,
Cerundolo V, Ferrarini M, Barnaba V: Apoptotic cells overexpress vinculin
and induce vinculin-specific cytotoxic T-cell cross-priming. Nat Med 2001,
7:807-813.
Zhang et al. Proteome Science 2010, 8:12
http://www.proteomesci.com/content/8/1/12
Page 11 of 1237. Jimenez-Baranda S, Gomez-Mouton C, Rojas A, Martinez-Prats L, Mira E, Ana
Lacalle R, Valencia A, Dimitrov DS, Viola A, Delgado R, Martinez AC,
Manes S: Filamin-A regulates actin-dependent clustering of HIV
receptors. Nat Cell Biol 2007, 9:838-846.
38. Umeda T, Kouchi Z, Kawahara H, Tomioka S, Sasagawa N, Maeda T,
Sorimachi H, Ishiura S, Suzuki K: Limited proteolysis of filamin is catalyzed
by caspase-3 in U937 and Jurkat cells. J Biochem 2001, 130:535-542.
39. Tandon R, Levental I, Huang C, Byfield FJ, Ziembicki J, Schelling JR,
Bruggeman LA, Sedor JR, Janmey PA, Miller RT: HIV infection changes
glomerular podocyte cytoskeletal composition and results in distinct
cellular mechanical properties. Am J Physiol Renal Physiol 2007, 292:
F701-710.
40. Boutet A, Altmeyer R, Hery C, Tardieu M: Direct role of plasma membrane-
expressed gp120/41 in toxicity to human astrocytes induced by HIV-1-
infected macrophages. Aids 2000, 14:2687-2697.
41. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M:
Global, in vivo, and site-specific phosphorylation dynamics in signaling
networks. Cell 2006, 127:635-648.
42. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, Schlautman JD, Ciborowski P,
Volsky DJ, Gendelman HE: HIV-1-infected astrocytes and the microglial
proteome. J Neuroimmune Pharmacol 2008, 3:173-186.
43. Gupta N, Shankernarayan NP, Dharmalingam K: Serum proteome of
leprosy patients undergoing erythema nodosum leprosum reaction:
regulation of expression of the isoforms of haptoglobin. J Proteome Res
2007, 6:3669-3679.
44. Wood TC, Aksoy IA, Aksoy S, Weinshilboum RM: Human liver thermolabile
phenol sulfotransferase: cDNA cloning, expression and characterization.
Biochem Biophys Res Commun 1994, 198:1119-1127.
45. Lorenz MW, Stephan C, Harmjanz A, Staszewski S, Buehler A, Bickel M, von
Kegler S, Ruhkamp D, Steinmetz H, Sitzer M: Both long-term HIV infection
and highly active antiretroviral therapy are independent risk factors for
early carotid atherosclerosis. Atherosclerosis 2008, 196:720-726.
46. Niu J, Profirovic J, Pan H, Vaiskunaite R, Voyno-Yasenetskaya T: G Protein
betagamma subunits stimulate p114RhoGEF, a guanine nucleotide
exchange factor for RhoA and Rac1: regulation of cell shape and
reactive oxygen species production. Circ Res 2003, 93:848-856.
47. Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE,
Schubert U, Henklein P, Orenstein JM, Sporn MB, Wahl SM: Human
immunodeficiency virus type 1-induced macrophage gene expression
includes the p21 gene, a target for viral regulation. J Virol 2005,
79:4479-4491.
48. Wahl SM, Greenwell-Wild T, Peng G, Ma G, Orenstein JM, Vazquez N: Viral
and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc
Biol 2003, 74:726-735.
49. Olsen KE, Sletten K, Westermark P: Extended analysis of AL-amyloid
protein from abdominal wall subcutaneous fat biopsy: kappa IV
immunoglobulin light chain. Biochem Biophys Res Commun 1998,
245:713-716.
50. Shoeman RL, Hartig R, Hauses C, Traub P: Organization of focal adhesion
plaques is disrupted by action of the HIV-1 protease. Cell Biol Int 2002,
26:529-539.
doi:10.1186/1477-5956-8-12
Cite this article as: Zhang et al.: Proteomic analysis of PBMCs:
characterization of potential HIV-associated proteins. Proteome Science
2010 8:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. Proteome Science 2010, 8:12
http://www.proteomesci.com/content/8/1/12
Page 12 of 12